We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 123

Lundbeck v. Cobalt and Ratiopharm

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 19 2009

Lundbeck brought a judicial review of the Minister's decision to accept the generic companies' ANDSs for their brand of memantine

Sanofi-Aventis v. Novopharm; preliminary questions regarding costs assessment

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 2 2009

Sanofi had brought a proceeding against Novopharm and joined Schering as the respondentpatentee pursuant to the NOC Regulations

Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record

Apotex v AstraZeneca; motion to strike parts of a statement of claim in a Section 8 proceeding

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 15 2007

The Court dismissed the appeal of a Prothonotary's decision refusing to strike parts of the Statement of Claim

Altana Pharma v Novopharm

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 16 2007

The Federal Court found that each side is limited to five experts in a case, subject to requesting leave of the Court to vary that number

Lilly v Novopharm; decision on motion for leave to intervene; October 23, 2007 - olanzapine

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 16 2007

Four trade associations sought leave to intervene in an appeal of a 55.2 proceeding, namely the Canadian Chamber of Commerce, BIOTECanada, Canada's Research-Based Pharmaceutical Companies and the Canadian Generic Pharmaceutical Association

Lilly v Novopharm; motion to dismiss appeal for mootness; November 6, 2007 - olanzapine

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 16 2007

The Federal Court of Appeal heard the respondent generic company's motion to dismiss the appeal on the basis of mootness

Apotex v Servier; appeal of interlocutory motion; November 1, 2007 - perindopril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 16 2007

The Federal Court of Appeal overturned the decision of the Federal Court and reinstated a number of paragraphs in the Statement of Defence and Counterclaim relating to the issue of inventorship

Sanofi-Aventis v Riva, preliminary motion to dismiss a judicial review proceeding; November 7, 2007 - rampiril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 6 2007

The Minister of Health had sent a letter to the generic company indicating that once it had satisfied the requirements of the NOC Regulations, it would be eligible to receive a NOC regardless of whether the other generic company to which it had cross-referenced its submission had satisfied all of the NOC Regulations and received a NOC

Servier v Apotex, interlocutory motion in an infringement action; November 19, 2007 - perindopril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 6 2007

By this motion, two additional innovator companies sought leave to be added as defendants to Apotex's counterclaim against Servier under the Competition Act